Irritable Bowel Syndrome (IBS) Treatment Market is Booming Worldwide Scrutinized in New Research

SUBMITTED BY: nikhilghodse20051994

DATE: July 27, 2022, 1:30 p.m.

FORMAT: Text only

SIZE: 3.6 kB

Raw Download

HITS: 454

Report
  1. The irritable bowel syndrome (IBS) treatment market was valued at US$ 2,153.89 million in 2020 and is projected to reach US$ 4,600.30 million by 2028; it is expected to grow at a CAGR of 10.1% from 2021 to 2028.
  2. The growth of the irritable bowel syndrome (IBS) treatment market is primarily attributed to the key driving factors such as increasing IBS diseases prevalence and rising research & development activities. However, the limited number of product availability and treatment inefficiency hinder the market growth. Ironwood Pharmaceuticals, Inc.; AbbVie.; Sebela Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Alfasigma S.p.A.; Astellas Pharma Inc.; AstraZeneca; Synthetic Biologics, Inc.; Bausch + Lomb Incorporated; and Lannett Company Inc are among the leading companies operating in the market.
  4. Get Sample PDF:
  5. https://www.theinsightpartners.com/sample/TIPRE00006814/
  7. Based on type, the irritable bowel syndrome (IBS) treatment market is segmented into mixed IBS (IBS-M), IBS with diarrhea (IBS-D), and IBS with constipation (IBS-C). The mixed IBS (IBS-M) segment held the largest share of the market in 2020. Also, the same segment is expected to register the highest CAGR during 2021–2028. In the coming years, the rising prevalence of IBS among women and men is anticipated to propel the demand for the medicines that can treat combined symptoms of constipation and diarrhea. According to updated Rome IV criteria, the reverse condition of IBS-M is described as a model of hard or irregular stools in more than 25% of bowel movements. The prevalence is higher in the geriatric population. Therefore, the demand for medicines to treat mixed IBS is likely to grow significantly during the forecast period,
  9. Buy Now: https://www.theinsightpartners.com/buy/TIPRE00006814/
  11. The report segments global irritable bowel syndrome (IBS) treatment market as Follows:
  13. By Type
  14. • IBS with Diarrhea (IBS-D)
  15. • IBS with Constipation (IBS-C)
  16. • Mixed IBS (IBS-M)
  17. By Product
  18. • Rifaximin
  19. • Eluxadoline
  20. • Linaclotide
  21. • Lubiprostone
  22. • Others
  23. By Distribution Channel
  24. • Hospitals Pharmacies
  25. • Drug Stores and Retail Pharmacies
  26. • Online Pharmacies
  27. By Geography
  28. • North America
  29. o
  30.  US
  31.  Canada
  32.  Mexico
  33. • Europe
  34. o
  35.  France
  36.  Germany
  37.  UK
  38.  Spain
  39.  Italy
  40.  Rest of Europe
  43. • Asia Pacific (APAC)
  44. o
  45.  China
  46.  India
  47.  Japan
  48.  Australia
  49.  South Korea
  50.  Rest of APAC
  52. • Middle East and Africa (MEA)
  53. o
  54.  Saudi Arabia
  55.  UAE
  56.  South Africa
  57.  Rest of MEA
  59. • South and Central America (SCAM)
  60. o
  61.  Brazil
  62.  Argentina
  63.  Rest of SCAM
  66. Company Profiles
  67. • Ironwood Pharmaceuticals, Inc.
  68. • AbbVie.
  69. • Sebela Pharmaceuticals, Inc.
  70. • Takeda Pharmaceutical Company Limited
  71. • Alfasigma S.p.A.
  72. • Astellas Pharma Inc.
  73. • AstraZeneca
  74. • Synthetic Biologics, Inc.
  75. • Bausch + Lomb Incorporated
  76. • Lannett Company Inc
  77. About Us:
  78. The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
  79. Contact Us:
  80. If you have any queries about this report or if you would like further information, please contact us:
  81. Contact Person: Sameer Joshi
  82. E-mail: sales@theinsightpartners.com
  83. Phone: +1-646-491-9876
comments powered by Disqus